Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964447 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL295597 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5161815 | 0.69 | GRM8 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL30369747 | 0.68 | SMN1; SMN2 (0.36) | DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8043620 | 0.61 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL215360 | 0.61 | — | — | |
| SCHEMBL9227569 | 0.61 | — | — | |
| SCHEMBL20629534 | 0.61 | — | — | |
| SCHEMBL21345145 | 0.61 | — | — | |
| SCHEMBL8313066 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208085-B | Modified release formulations of 1- [ (3-hydroxy-adamantyl-1-ylamino) -acetyl ] -pyrrolidinyl-2(s) -carbonitrile | NOVARTIS AG | 2011-01-05 | — | — | CN | disclosed |
| CN-101208085-A | Modified release formulations of 1- [ (3-hydroxy-adamantyl-1-ylamino) -acetyl ] -pyrrolidinyl-2(s) -carbonitrile | NOVARTIS AG (CH) | 2008-06-25 | — | — | CN | disclosed |
| EP-1898904-A2 | MODIFIED RELEASE 1-[(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL]-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION | Novartis AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| CN-101035568-A | Combination therapy using transferrin fusion proteins comprising GLP-1 | BIOREXIS PHARMACEUTICAL CORP (US) | 2007-09-12 | — | — | CN | disclosed |
| WO-2006135723-A2 | MODIFIED RELEASE 1-[(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL]-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | disclosed |